PARP inhibitors in prostate cancers, is it time for combinations? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Therapeutic Advances in Medical Oncology Année : 2024

PARP inhibitors in prostate cancers, is it time for combinations?

Diego Teyssonneau
Eric Barret
Gilles Créhange Crehange
  • Fonction : Auteur
  • PersonId : 782378
  • IdRef : 077502469
Mathieu Gauthé
Paul Sargos
Guilhem Roubaud
  • Fonction : Auteur
  • PersonId : 975634

Résumé

Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disease. Olaparib and rucaparib, two poly-ADP-ribose polymerase (PARP) inhibitors, have received approval from the authorities of several countries for their anti-tumoral effects in patients with metastatic castration-resistant prostate cancers harboring HRR gene alterations, in particular BRCA2. More recently, it has been hypothesized that new hormonal therapies (NHTs) and PARP inhibitors (PARPi) could have synergistic actions and act independently of HRR deficiency. This review proposes to discuss the advantages and disadvantages of PARPi used as monotherapy or in combination with NHTs and whether there is a need for molecular selection.

Domaines

Cancer
Fichier principal
Vignette du fichier
main.pdf (711.46 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-04605172 , version 1 (06-09-2024)

Licence

Identifiants

Citer

Diego Teyssonneau, Charles Dariane, Eric Barret, Jean Baptiste Beauval, Laurent Brureau, et al.. PARP inhibitors in prostate cancers, is it time for combinations?. Therapeutic Advances in Medical Oncology, 2024, 16, pp.17588359241242959. ⟨10.1177/17588359241242959⟩. ⟨hal-04605172⟩
67 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More